Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Pipeline Review, H2 2016

Publisher Name :
Date: 16-Nov-2016
No. of pages: 86

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Global Markets Direct's, ‘Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Pipeline Review, H2 2016', provides in depth analysis on Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope


  • The report provides a snapshot of the global therapeutic landscape for Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1)

  • The report reviews Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics


Reasons to buy


  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) Overview 7
Therapeutics Development 8
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Products under Development by Stage of Development 8
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Products under Development by Therapy Area 9
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Products under Development by Indication 10
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Products under Development by Companies 14
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Companies Involved in Therapeutics Development 24
Aerpio Therapeutics, Inc. 24
Deciphera Pharmaceuticals, LLC 25
Eddingpharm 26
Exelixis, Inc. 27
Pfizer Inc. 29
PharmAbcine, Inc. 30
Teva Pharmaceutical Industries Ltd. 31
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Drug Profiles 32
altiratinib - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
AP-102 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
ARP-1536 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
cabozantinib s-malate - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
CEP-11981 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
EDP-317 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
PMC-001 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
rebastinib tosylate - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Small Molecule to Antagonize Tie-2 Receptor for Solid Tumor - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Dormant Projects 62
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Discontinued Products 64
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Featured News & Press Releases 65
Oct 31, 2016: Deciphera Pharmaceuticals to Present Clinical Data on Altiratinib at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 65
Oct 10, 2016: Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016 65
Oct 07, 2016: Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors 67
Oct 03, 2016: CABOMETYX (cabozantinib) Tablets Approved for Advanced Renal Cell Carcinoma, Available at Biologics 68
Sep 27, 2016: Ipsen Announces Data Presentations of Cabozantinib (Cabometyx) at the European Society for Medical Oncology (ESMO) 2016 Congress 69
Sep 20, 2016: Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016 Congress 70
Sep 14, 2016: European Commission Approves Ipsens Cabometyx (Cabozantinib) Tablets For The Treatment Of Advanced Renal Cell Carcinoma In Adults Following Prior Vascular Endothelial Growth Factor (Vegf)-Targeted Therapy 71
Sep 06, 2016: Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of Cabozantinib in Patients with Advanced Hepatocellular Carcinoma 72
Aug 31, 2016: Exelixis presents cabozantinib data at the ESMO 2016 Congress 73
Jul 22, 2016: Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy 76
Jun 05, 2016: Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO 77
May 23, 2016: Ipsen's partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma 79
Apr 26, 2016: Diplomat to Dispense CABOMETYX (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma 80
Apr 25, 2016: Exelixis Announces FDA Approval of CABOMETYX (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy 80
Apr 20, 2016: Exelixis Announces Presentation On Cabozantinib At 2016 ASCO Annual Meeting 82
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 85
Disclaimer 86

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 (Contd..1) 16
Products under Development by Companies, H2 2016 (Contd..2) 17
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 20
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Pipeline by Aerpio Therapeutics, Inc., H2 2016 24
Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016 25
Pipeline by Eddingpharm, H2 2016 26
Pipeline by Exelixis, Inc., H2 2016 27
Pipeline by Pfizer Inc., H2 2016 29
Pipeline by PharmAbcine, Inc., H2 2016 30
Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 31
Dormant Projects, H2 2016 62
Dormant Projects (Contd..1), H2 2016 63
Discontinued Products, H2 2016 64

List of Figures

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Top 10 Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Mechanism of Actions, H2 2016 19
Number of Products by Stage and Mechanism of Actions, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 21
Number of Products by Molecule Types, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 22

  • Global Procalcitonin Antibody Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Jun-2018        Price: US 3480 Onwards        Pages: 152
    Procalcitonin (PCT) is a 116 amino acid residue protein with a molecular weight of approximately 13kDa. Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin. It can be expressed in E. coli.Procalcitonin Antibody refers to the specific protein which can qualitatively and quantit......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Procalcitonin Antibody Market 2018, Forecast to 2023
    Published: 15-Jun-2018        Price: US 4880 Onwards        Pages: 150
    Procalcitonin (PCT) is a 116 amino acid residue protein with a molecular weight of approximately 13kDa. Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin. It can be expressed in E. coli.Procalcitonin Antibody refers to the specific protein which can qualitatively and quantit......
  • Global Epidermal Growth Factor (EGF) (CAS 62253-63-8) Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Jun-2018        Price: US 3480 Onwards        Pages: 132
    Epidermal growth factor (EGF) is a growth factor that stimulates cell growth, proliferation, and differentiation by binding to its receptor EGFR. Human EGF is a 6045-Da protein with 53 amino acid residues and three intramolecular disulfide bonds EGF results in cellular proliferation, differentiation, and survival. EGF considerably increases skin cell regeneration. More precisely, they can directly communicate to the skin cells to produce more collagen and elastin, that's why most sk......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Epidermal Growth Factor (EGF) (CAS 62253-63-8) Market 2018, Forecast to 2023
    Published: 15-Jun-2018        Price: US 4880 Onwards        Pages: 136
    Epidermal growth factor (EGF) is a growth factor that stimulates cell growth, proliferation, and differentiation by binding to its receptor EGFR. Human EGF is a 6045-Da protein with 53 amino acid residues and three intramolecular disulfide bonds EGF results in cellular proliferation, differentiation, and survival. EGF considerably increases skin cell regeneration. More precisely, they can directly communicate to the skin cells to produce more collagen and elastin, that's why most sk......
  • Creatinine Measurement Market by Product (Kits, Reagents), Test Type (Jaffe method, Enzymatic creatinine method), Sample (Serum Creatinine, Urine) and End User (Hospitals, Diagnostic Laboratories), Region (North America, Europe) - Global Forecast to 2023
    Published: 11-Jun-2018        Price: US 5650 Onwards        Pages: 210
    “The global creatinine measurement market projected to grow at a CAGR of 8.4%.” The global creatinine measurement market is expected to reach USD 564.5 million by 2023 from USD 377.2 million in 2018, at a CAGR of 8.4%. Factors such as the increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, favorable government initiatives to promote renal health, rapid growth in the geriatric population, ......
  • Global Human Micobiome Market by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 09-Jun-2018        Price: US 3480 Onwards        Pages: 152
    The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bact......
  • Global Microbial Identification Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 08-Jun-2018        Price: US 3480 Onwards        Pages: 150
    Microbial identification is the process of identifying harmful bacteria and fungi that may contaminate raw materials, manufacturing facilities and branded products. Accurate and definitive microbial identification is critical for disease diagnosis and treatment of infections. Bacterial identification is widely used across manufacturing facilities, clinical settings and environmental studies. In this report our statistical date only content monitoring equipment. Scope of the Report......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Microbial Identification Market 2018, Forecast to 2023
    Published: 08-Jun-2018        Price: US 4880 Onwards        Pages: 145
    Microbial identification is the process of identifying harmful bacteria and fungi that may contaminate raw materials, manufacturing facilities and branded products. Accurate and definitive microbial identification is critical for disease diagnosis and treatment of infections. Bacterial identification is widely used across manufacturing facilities, clinical settings and environmental studies. In this report our statistical date only content monitoring equipment. Scope of the Report......
  • Multiplex Assays Market by Product (Consumables, Instruments), Type (Nucleic Acid, Protein, Cell), Technology (Flow Cytometry, Luminescence), Application (R&D, Diagnosis), End User (Pharma & Biotech, Reference Laboratory, Hospital) - Global Forecast to 2023
    Published: 07-Jun-2018        Price: US 5650 Onwards        Pages: 142
    “The global multiplex assays market is projected to grow at a CAGR of 7.5%.” The global multiplex assays market is projected to reach USD 3.35 billion in 2023 from USD 2.33 billion in 2018, at CAGR of 7.5%. Multiplex assays enable the simultaneous detection of multiple analytes in a single run/cycle of the assay. The use of multiplex assays in companion diagnostics for increasing the safety & efficacy of therapies and the advantages of multiplex assays......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs